Meissa Vaccines’ intranasal live attenuated chimeric virus-based vaccine for SARS-CoV-2 (and its variants), which was cleared for Phase I trials, employs codon deoptimization to evoke a stronger-than-usual immune response.
Vir Biotechnology, Eli Lilly and GlaxoSmithKline struck a three-way collaborative deal to evaluate Vir’s investigational monoclonal antibody VIR-7831 in combination with Lilly’s bamlanivimab in low-risk patients with mild to moderate Covid-19.
Moderna started development on a booster to the company’s Covid-19 vaccine, which is hoped to work against the recently discovered (and more transmissible) SARS-CoV-2 variant from South Africa.
The U.S. Food and Drug Administration gave Emergency Use Authorization (EUA) to a Covid-19 test developed by Roche that measures antibodies within the blood.
Researchers at Johns Hopkins Medicine identified a protein – known as factor D – that appears essential to the inflammatory process of SARS-CoV-2, the virus that causes Covid-19.
BioSpace reviews some of the more interesting recently published scientific studies, including whether the Covid-19 virus relieve pain.
President Donald Trump was treated with an experimental antibody cocktail for Covid-19 and moved to a military hospital as a precautionary measure, White House officials said.
iBio Inc. is developing a decoy molecule as a therapeutic against SARS-CoV-2.